Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study

por Haak, T, Meinicke, T, Jones, R, Weber, S, von Eynatten, M, Woerle, H-J
Publicado 2013

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

por Salsali, A., Kim, G., Woerle, H. J., Broedl, U. C., Hantel, S.
Publicado 2016

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

por Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U. C., Woerle, H. J.
Publicado 2015

Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone:...

por Bajaj, M, Gilman, R, Patel, S, Kempthorne-Rawson, J, Lewis-D'Agostino, D, Woerle, H-J
Publicado 2014

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

por Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., Johansen, O. E.
Publicado 2015

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)

por Pieber, T. R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O. E., Woerle, H. J., Broedl, U. C., Kaspers, S.
Publicado 2015

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

por Groop, P-H, Del Prato, S, Taskinen, M-R, Owens, D R, Gong, Y, Crowe, S, Patel, S, von Eynatten, M, Woerle, H-J
Publicado 2014